Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
RNA interference
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "RNA interference" in MCE Product Catalog:
10
10 Publications Verification
Cat. No.: HY-W020772
CAS No.: 996-19-0
Target:
Research Areas:
Aminoguanidine hemisulfate is an inhibitor of NOS and ROS. Aminoguanidine hemisulfate abolishes ANE-induced ROS production in vitro. Aminoguanidine hemisulfate is used for cancer research .
1
1 Cited Publications
Synonyms: DSPE-mPEG2000 sodium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium
1
Research Areas:
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .
1
1 Cited Publications
Research Areas:
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
1
Research Areas:
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .
Cat. No.: HY-147425
CAS No.: 2646703-64-0
Synonyms: SLN360
Research Areas:
Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Cat. No.: HY-145720
CAS No.: 1639264-46-2
Synonyms: ALN-CC5
Research Areas:
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
Synonyms: DAQ B1; L-783281; Dimethylasterriquinone
Target:
Insulin Receptor Akt NO Synthase NADPH Oxidase JAK STAT FOXO DNA/RNA Synthesis ERK Flavivirus
Research Areas:
Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology
Demethylasterriquinone B1 (DAQ B1; L-783281) is an orally active insulin receptor (insulin receptor) agonist and AKT activator. By activating AKT, Demethylasterriquinone B1 upregulates the expression and activity of eNOS to increase NO production, while downregulating the expression of the NADPH oxidase subunit p22phox to reduce oxidative stress and improve vascular endothelial dysfunction in hypertensive rats. Demethylasterriquinone B1 combind with an AKT inhibitor targets the insulin signaling pathway to activate two antiviral pathways, RNA interference and JAK/STAT, in mosquitoes, thereby reducing Zika virus infection .
Cat. No.: HY-147425A
Purity: 95.52%
Synonyms: SLN360 sodium
Research Areas:
Zerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Target:
Research Areas:
PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects .
Cat. No.: HY-132590A
Purity: 93.16%
Synonyms: ALN-TTRSC sodium
Research Areas:
Revusiran (ALN-TTRSC) sodium is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran sodium mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran sodium exhibits favorable nonclinical safety profiles. Revusiran sodium can be used in studies related to transthyretin-mediated amyloidosis .
Synonyms: QPI-1002 sodium
Teprasiran sodium is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI) .
Cat. No.: HY-132595
CAS No.: 1231737-88-4
Synonyms: QPI-1002
Research Areas:
Teprasiran (QPI-1002) is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI) .
Cat. No.: HY-132590
CAS No.: 1438322-82-7
Synonyms: ALN-TTRSC
Research Areas:
Revusiran (ALN-TTRSC) is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran exhibits favorable nonclinical safety profiles. Revusiran can be used in studies related to transthyretin-mediated amyloidosis .
Cat. No.: HY-145649
CAS No.: 2380166-33-4
Synonyms: AD-85481; ALN-AGT
Target:
Research Areas:
Zilebesiran is a siRNA that reduce hepatic angiotensinogen levels through RNA interference. it is used for the study of mild to moderate Hypertension. Angiotensinogen is the predominant precursor of angiotensin peptides and a key regulator of systemic blood pressure.
Target:
Research Areas:
CBB1007 hydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 hydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 hydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 hydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
Cat. No.: HY-147425D
Synonyms: FAM labled SLN360 sodium
Research Areas:
FAM labled Zerlasiran sodium is a FAM labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Cat. No.: HY-147425E
Synonyms: Cy3 labled SLN360 sodium
Research Areas:
Cy3 labled Zerlasiran sodium is a Cy3 labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Cat. No.: HY-147425C
Synonyms: SLN360 sodium scrambled negative control
Research Areas:
Zerlasiran (SLN360) sodium scrambled negative control is the sequence scrambled negative control of Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Cat. No.: HY-K0002
MCE Bacterial Protein Extraction Reagent integrates both lysozyme and nuclease activities and is specifically formulated for E. coli lysis. It efficiently disrupts the peptidoglycan layer under mild conditions to rapidly release intracellular proteins. Simultaneously, the incorporated nucleases degrade genomic DNA/RNA, significantly reducing lysate viscosity and minimizing nucleic-acid interference, thereby preserving the native conformation and functional integrity of target proteins to the greatest extent.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
